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Abstract 
Accumulating evidence indicates the crucial contribution of chronic inflammation to various 
types of carcinogenesis, including colon carcinoma associated with ulcerative colitis and 
asbestosis-induced malignant mesothelioma. Ulcerative colitis-associated colon 
carcinogenesis can be recapitulated in mice by azoxymethane (AOM) administration 
followed by repetitive dextran sulfate sodium (DSS) ingestion. In the course of this 
carcinogenesis process, the expression of a macrophage-tropic chemokine, CCL2, was 
enhanced together with intracolonic massive infiltration of macrophages, which were a major 
source of cyclooxygenase (COX)-2, a crucial mediator of colon carcinogenesis. Mice 
deficient in CCL2-specific receptor, CCR2, exhibited less macrophage infiltration and lower 
tumor numbers with attenuated COX-2 expression. Moreover, CCL2 antagonists decreased 
intracolonic macrophage infiltration and COX-2 expression, attenuated neovascularization, 
and eventually reduced the numbers and size of colon tumors, even when given after multiple 
colon tumors have developed. These observations identify CCL2 as a crucial mediator of the 
initiation and progression of chronic colitis-associated colon carcinogenesis and suggest that 




Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD), an 
immune-mediated chronic intestinal condition (1). The major symptom of UC is bloody 
mucoid diarrhea and its clinical course is characterized by repetitive relapses and remissions. 
Pathological features of UC include prominent leukocyte infiltration in the colonic mucosa 
and uncontrolled and prolonged inflammatory reactions (1). These conditions frequently 
cause epithelial dysplasia and DNA damage with microsatellite instability, and eventually can 
progress to cancer (2). Indeed, involvement of entire colon for longer than 10 years 
predisposes UC patients to colon cancer (2), indicating the essential contribution of chronic 
inflammation to colon carcinogenesis. Thus, to develop measures to prevent cancer 
development in UC patients it is necessary to gain an understanding of the pathogenesis of 
UC at molecular and cellular levels. Moreover, evidence is accumulating that chronic 
inflammatory conditions also can cause cancer in other organs as observed on asbestosis and 
silicosis (3). Thus, elucidation of colon carcinogenesis in UC will also shed a novel light on 
chronic inflammation-associated carcinogenesis in general. 
Oral administration of dextran sulfate sodium (DSS) to rodents is widely used to 
recapitulate human UC, because it can induce pathological changes similar to that observed 
in UC patients (4). Moreover, repeated oral DSS ingestion can cause colon carcinoma (5) and 
this carcinogenesis process is promoted by a prior administration of azoxymethane (AOM), 
which causes O6-methyl-guanine formation (6). Activation of NF-κB pathway contributes to 
this colon carcinogenesis by preventing colon epithelial cell apoptosis and promoting growth 
factor production by inflammatory cells (7). The crucial involvement of NF-κB activation in 
colon carcinogenesis prompted us to investigate the roles of the tumor necrosis factor 
(TNF)-α/TNF receptor axis, because TNF-α is abundantly expressed in colon of patients with 
IBD (8), and is one of major target molecules of NF-κB and a major activator of NF-κB (9). 
We showed that combined treatment with AOM and DSS induced the intracolonic expression 
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of TNF-α, which in turn regulates the trafficking of macrophages and granulocytes, major 
sources of cycolooxygenase (COX)-2, thereby resulting in the development and progression 
of colon cancer (10). 
TNF-α lacks direct chemotactic activities for macrophages and granulocytes, but can 
induce the expression of various chemokines in several cell types present in colon tissues 
such as epithelial cells, fibroblasts, endothelial cells, and leukocytes (9). Thus, it is likely that 
enhanced TNF-α expression in colon tissues can induce the expression of chemokines active 
on macrophages and granulocytes. Indeed, the mucosa of patients with IBD exhibited 
enhanced mRNA and protein expression of MCP-1/CCL2 (11-13), a C-C chemokine with 
potent chemotactic and activating activities for monocytes/macrophages (14). We previously 
consistently observed that combined treatment of AOM and DSS enhanced CCL2 mRNA 
expression in colon tissues and that blocking the TNF-α/TNF receptor axis reduced colorectal 
carcinogenesis, intracolonic macrophage infiltration, and CCL2 mRNA expression (10). 
These observations prompted us to investigate the roles of the interaction between CCL2 and 
its specific receptor, CCR2, in colon carcinogenesis induced by the combined treatment with 
AOM and DSS. By using CCR2-deficient mice and CCL2 blocking agents, we here 
document that CCL2 interactions with CCR2 have vital roles in the initiation and progression 
of colitis-associated colon carcinogenesis. 
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Materials and Methods 
 
Reagents and antibodies 
AOM and DSS (MW 36,000-50,000) were purchased from Sigma-Aldrich, Inc. (St. Louis, 
MO) and MP Biomedicals Inc. (Aurora, OH), respectively. A specific CCR2 antagonist, 
propagermanium, was kindly provided by Sanwa Chemical Co. (Osaka, Japan). Human 
CCL2 N-terminal deleted form (7ND)-expressing vector was prepared by cloning human 
CCL2 N-terminal deleted cDNA with an epitope FLAG tag in the carboxyl terminal portion 
to the pcDNA3 expression vector as described previously (15). Rat monoclonal anti-F4/80 
antibody was obtained from Serotec (Oxford, United Kingdom). Goat polyclonal anti-COX-2 
and mouse monoclonal anti-cytokeratin 20 antibodies were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA) and Abcam (Cambridge, UK), respectively. Rabbit 
polyclonal anti-β-catenin and mouse monoclonal ANTI-FLAG® M2 antibodies were from 
Sigma-Aldrich, Inc. Rat monoclonal anti-CD31 antibody was from BD Biosciences 
Pharmingen (Franklin Lakes, NJ). Rabbit polyclonal anti-CCL2 and anti-CCR2 antibodies 
were prepared by immunizing rabbits with mouse CCL2 protein and CCR2 peptide as 
previously described (16). 
 
Animal experiments 
Pathogen-free 8- to 12-week old female wild-type BALB/c mice (WT) and CCR2-deficient 
mice, on a BALB/c genetic background, were housed under specific pathogen-free conditions 
with free access to food and water during the course of experiments. Mice were injected 
intraperitoneally with 12 mg/kg body weight of AOM dissolved in physiological saline. Five 
days later, 2 % DSS was given in the drinking water over five days, followed by 16 days of 
regular water. This cycle was repeated a total of 3 times. Body weights were measured every 
week and the animals were sacrificed at the indicated time intervals for macroscopical 
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inspection, histological analysis, and total RNA extraction.  In some experiments, 
7ND-expressing or pcDNA3 vector was injected into the femoral muscle of WT mice at day 
56. Immediately after the injection, a pair of electrode pads was inserted onto the muscle to 
encompass the injected site, and electrical pulses were delivered 6 times (100V, 50- ms pulse) 
with an electrical pulse generator (ECM830; BTX, San Diego, CA). At 11 days after the 
transfection, immunohistochemical analysis detected 7ND protein in the muscle of WT mice 
receiving 7ND-expressing vector, but not those receiving pcDNA3 vector (Supplemental Fig. 
1). In another series of experiments, WT mice were given propagermanium at a dose of 8 
mg/kg body weight, mixed with the food, every day from day 56 to day 60. All animal 
experiments were performed in compliance with the Guideline for the Care and Use of 
Laboratory Animals of Kanazawa University. 
 
Bone marrow chimeric mice generation 
Cell suspensions from male WT or CCR2-deficient bone marrow were prepared from femurs 
and tibias, filtered and counted. Female WT or CCR2-deficient mice received a single 
intravenous injection of 1 x 107 bone marrow cells, after being irradiated with 4.25 Gy X-rays 
followed by 4.25 Gy X-rays (MPR-1520R; Hitachi) 4 hours later. The following groups of 
chimeric mice were generated: WT to WT, WT to CCR2-deficient, CCR2-deficient to WT, 
and CCR2-deficient to CCR2-deficient mice. Genomic DNA was extracted from blood and 
bone marrow chimerism was determined 4 weeks later by PCR for the Y chromosome-linked 
Sry gene (forward, 5’-TGGGACTGGTGACAATTGTC-3’; reverse, 5’- 
GAGTACAGGTGTGCAGCTCT-3’). 
 
Histopathological and immunohistochemical analyses of mouse colon tissues 
Resected mouse colon tissues were fixed in 10 % formalin neutral buffer solution (Wako 
Chemical, Osaka, Japan) for paraffin embedding or were immediately frozen in Tissue-Tek 
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O.C.T. compound (Sakura Fine Technical Co., Tokyo, Japan) and stored at -80ºC. 
Paraffin-embedded sections were cut at 5 μm and stained with hematoxylin and eosin 
solution. Paraffin-embedded sections were additionally deparaffinized for 
immunohistochemical detection of β-catenin-, CCR2-, CCL2-, F4/80-, Ly-6G-, COX-2-, 
cytokeratin 20-, and FLAG-positive cells. Frozen sections were used for 
immunohistochemical detection of mouse CD31-positive cells. Endogenous peroxidase 
activity was blocked using 3 % H2O2 for 5 minutes, followed by incubation with 
Non-Specific Staining Blocking reagent (DakoCytomation, Carpinteria, CA) for 10 min. The 
sections were incubated with the optimal dilutions of anti-CCR2, anti-CCL2, anti-F4/80, 
anti-CD3, anti-β-catenin, anti-COX-2, anti-CD31, anti-cytokeratin 20, or anti-FLAG 
antibodies overnight at 4ºC. β-catenin- and CCR2-positive cells were detected with 
horseradish peroxidase (HRP)-labelled anti-rabbit polymer (EnVision+ System, 
DakoCytomation), while F4/80-positive cells were detected using Catalyzed Signal 
Amplification (CSA) System (DakoCytomation). Immune complexes were visualized with 
Peroxidase Substrate DAB kit (Vector Laboratories, Inc., Burlingame, CA). CCL2-, COX-2-, 
and CD31-positive cells were detected by the incubation with anti-rabbit, anti-goat or anti-rat 
biotinylated IgG (DakoCytomation, dilution, 1:200). Detection of cytokeratin 20 and FLAG 
tag was performed with Vector® M.O.M.TM Immunodetection kit (Vector Laboratories, Inc.), 
according to the manufacturer’s instructions. The resultant immune complexes were 
visualized by ABC Elite kit (Vector Laboratories, Inc.) and Peroxidase Substrate DAB kit 
(Vector Laboratories, Inc.) according to the manufacturer’s instructions. Finally, the slides 
were counterstained with hematoxylin, dehydrated and coverslipped. Positive cells were 
enumerated on 5 randomly chosen visual fields at x 400 magnification. The pixel numbers of 
CD31-positive areas were measured on 5 randomly chosen visual fields at x 200 
magnification with the aid of Adobe Photoshop software. 
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A double-color immunofluorescence analysis 
Colon tissues were processed to a double-color immunofluorescence analysis using the 
combination of anti-CCR2 and anti-COX-2 antibodies. Alexa Fluor® 488 donkey anti-rabbit 
and Alexa Fluor® 546 donkey anti-goat antibodies were used as secondary antibodies. 
Immunofluorescence was visualized on a Carl Zeiss Laser Scanning Microscope 510. 
 
RT-PCR analysis 
Total RNA was extracted from colon tissues with RNeasy® Mini Kit (Qiagen) and 2.5 μg of 
RNA was reverse-transcribed using ReverTraAce (Toyobo, Japan) and random primers as 
described previously (10). Thereafter, 2 μl of resultant cDNA was used for amplification 
using Taq DNA polymerase (Takara Shuzo, Japan) and 10 μM of specific sets of primers with 
the pre-determined optimal cycle consisting of 94ºC for 30 sec, 55ºC for 1 min and 72ºC for 1 
min (Supplemental Table 1) as described previously. The PCR products were fractionated on 
1.5 % agarose gel and visualized by ethidium bromide staining. The band intensities were 
measured with the aid of NIH Image Analysis software version 1.62, and the ratios to 
GAPDH were determined. Real-time PCR was performed on Applied Biosystems StepOne™ 
Real-Time PCR System using the comparative CT quantitation method. TaqMan® Gene 
Expression Assays (Applied Biosystems, Foster City, CA), containing specific primers 
(accession numbers:  MCP-1/CCL2 – Mm00441242_m1, KC/CXCL1 – Mm00433859_m1, 
COX-2 – Mm00478374_m1, GAPDH – Mm99999915_g1) and TaqMan® MGB probe (FAM 
™ dye-labeled), TaqMan® Fast Universal PCR Master Mix were used with 10 ng of cDNA 
to detect and quantify the expression levels of CCL2 and COX-2 in mouse colon tissues. 
GAPDH was amplified as internal control. CT values of GAPDH were subtracted from CT 
values of the target genes (Δ CT). Δ CT values of treated mice were compared to Δ CT values of 




DNA sequencing and mutation analysis of β-catenin gene 
Genomic DNA was extracted from tumor tissues obtained from WT mice receiving either 
7ND-expressing or pcDNA3 vector by using NucleoSpin® Tissue Kit (Macherey-Nagel Inc.) 
according to the manufacturer’s instructions. Exon 3 of the β-catenin gene, containing the 
consensus sequence for glycogen synthase kinase-3β phosphorylation, was amplified by PCR, 
using specific primers (forward, 5’-GCTGACCTGATGGAGTTGGA-3’; reverse, 
5’-GCTACTTGCTCTTGCGTGAA-3’) and the following thermal cycling parameters: 35 
cycles of 94°C, 5 minutes; followed by 94°C, 45 seconds, 55°C, 1 minute, 72°C, 1 minute; 
followed by 72°C, 5 minutes. PCR products were subcloned into pSTBlue-1 vector 
(AccepTorTM vector, Novagen) and sequenced using BigDye® Terminator Ver. 3.1 Cycle 




The mean±S.D. were calculated for all parameters determined. Statistical significance was 
evaluated using one-way analysis of variance (ANOVA), and p values lower than 0.05 were 




Enhanced CCL2 expression in the colon during the course of colon carcinogenesis 
Consistent with our previous observations (10), a single intraperitoneal injection of the 
carcinogen AOM, followed by 3 rounds of 2% DSS intake, induced the development of 
multiple tumors from the middle to distal colon of wild-type (WT) mice (Fig. 1A and 
Supplemental Fig. 2). Because we previously observed a massive macrophage infiltration 
during the whole course of this colon carcinogenesis process, we investigated the expression 
of a macrophage-tropic chemokine MCP-1/CCL2 and its single specific receptor, CCR2. 
CCL2 mRNA expression level was negligible in untreated WT mice and immediately after 
AOM treatment, but subsequent to DSS administration CCL2 mRNA expression was 
augmented (Fig. 1B). CCL2 protein was detected in mononuclear cells infiltrating the lamina 
propria and submucosal regions, and also in endothelial cells at the earlier phase and colon 
carcinoma cells at the later phase (Fig. 1C). Immunohistochemical analysis demonstrated that 
CCR2 was expressed by mononuclear cells infiltrating in the lamina propria and submucosal 
regions of the colon, and by some colon carcinoma cells during the course of colon 
carcinogenesis (Fig. 1D). 
 
Reduction in AOM/DSS-induced inflammatory reaction and subsequent tumor 
formation in the absence of CCR2 
A massive infiltration of CCR2-positive cells prompted us to investigate the roles of the 
CCL2-CCR2 interactions in this colon carcinogenesis. There were no apparent differences in 
macroscopical and microscopical appearance of the colon of untreated WT and 
CCR2-deficient mice (Fig. 2A). When both strains were treated with AOM and DSS, WT 
mice exhibited marked body weight loss and bloody diarrhea, whereas CCR2-deficient mice 
showed a minimal body weight loss and diarrhea (data not shown). In WT mice, multiple 
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tumors extended from most of the middle to distal colon by day 56, whereas the numbers and 
sizes of tumors were remarkably reduced in the colons of CCR2-deficient mice even at day 
56 (Fig. 1A and Supplemental Fig. 2). Microscopical analysis consistently demonstrated that 
WT mice developed severe inflammation with massive infiltration of leukocytes into the 
mucosa, submucosal edema, and loss of entire crypts and surface epithelium, particularly in 
the middle to distal colon at day 7 (Fig. 2A). At day 14, inflammatory cell infiltration 
persisted, accompanied with dysplastic glands with hyperchromatic nuclei, decreased mucin 
production and dystrophic goblet cells. Moreover, immunohistochemical analysis 
demonstrated that inflammatory cells consisted of F4/80-positive macrophages (Fig. 2C). At 
days 28 to 35, adenocarcinomatous lesions with nuclear β-catenin accumulation appeared in 
the presence of macrophage and granulocyte infiltration, and their sizes and numbers 
increased progressively, thereafter (Fig. 2A, B). On the contrary, CCR2-deficient mice 
displayed only mild inflammatory changes in the colon during the course of DSS 
administration as evidenced by attenuated infiltration of macrophages (Fig. 2C) and 
eventually developed only a small number of adenocarcinomatous lesions with less nuclear 
β-catenin accumulation (Fig. 2A, B). These observations identified the CCL2-CCR2 
interactions as crucial for the development of chronic inflammation-associated colon 
carcinoma. 
 
Contribution of CCR2-expressing bone marrow-derived cells to colon carcinogenesis 
CCR2 is expressed by non-bone marrow as well as bone marrow-derived cells (17, 18) and 
we observed CCR2 expression on some cancer cells. Hence, we compared the contribution of 
CCR2-expressing non-bone marrow- and bone marrow-derived cells to this colon 
carcinogenesis by using bone marrow chimeric mice prepared from WT and CCR2-deficient 
mice. Upon combined treatment with AOM and DSS, CCR2-deficient and WT mice 
transplanted with WT mouse-derived bone marrow cells, developed tumors with a similar 
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incidence, but at a much higher level than either WT or CCR2-deficient mice transplanted 
with CCR2-deficient mouse-derived bone marrow (Fig. 3). These observations would 
indicate that CCR2-expressing bone marrow-derived cells, but not non-bone marrow-derived 
cells were mainly responsible for tumor development in this model. 
 
Reduction in AOM/DSS-induced expression of COX-2 in CCR2-deficient mice 
COX-2 mRNA expression and COX-2-expressing cell number were increased in WT mice 
following 7 days after the initiation of DSS treatment (Fig. 4A, B, C) as we previously 
observed (10). In line with our previous observation that COX-2 was expressed by 
F4/80-positive macrophages, double color immunofluorescence analysis revealed that the 
cells which expressed CCR2, also expressed COX-2 (Fig. 4D). AOM/DSS-induced increases 
in COX-2 mRNA expression and COX-2-positive cell numbers, were decreased in the 
absence of CCR2 (Fig. 4A, B, C). Collectively, AOM/DSS failed to increase the expression 
of COX-2, an enzyme that is crucially involved in colon carcinoma development, in 
CCR2-deficient mice. 
 
Reduction of tumor formation by CCR2 antagonist administration 
In order to further delineate the role of the CCL2-CCR2 interactions in the progression phase 
of this colon carcinogenesis model, we administered two distinct types of CCR2 antagonists, 
7ND-expressing vector and propagermanium, after three cycles of DSS intake, when multiple 
colon tumors have developed. When mice were treated with 7ND-expressing vector, the 
numbers and sizes of macroscopical tumors were markedly reduced (Fig. 5A, B). 
Histopathological analysis demonstrated that treatment with 7ND-expressing vector 
attenuated adenocarcinomatous changes (Figure 5C). Likewise, propagermanium treatment 
reduced the numbers and sizes of tumors and attenuated adenocarcinomatous changes 
(Supplemental Fig. 3A, B, C). Concomitantly, treatment with 7ND-expressing vector (Fig. 
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5D) or propagermanium (Supplemental Fig. 3D) decreased the numbers of infiltrating 
macrophages. 7ND administration reduced intracolonic COX-2 mRNA expression and 
COX-2-expressing cell numbers (Fig. 6A and Supplemental Fig. 4A). Moreover, 7ND 
treatment decreased intratumoral CD31-positive vascular areas significantly (Fig. 6B and 
Supplemental Figure 4B). Similarly, reductions in COX-2 expression and intratumoral 
vascular areas were observed with propagermanium treatment (Supplemental Fig. 5 and 6). 
Furthermore, 7ND treatment decreased nuclear accumulation of β-catenin in the tumor cells 
(Fig. 6C and Supplemental Fig.4C) and the numbers of cytokeratin 20-positive cells (Fig. 6D 
and Supplmental Fig. 4C). Likewise, propagermanium treatment decreased both β-catenin 
nuclear accumulation in the tumor cells and cytokeratin 20-positive cell numbers 
(Supplemental Fig. 7). Finally, the incidence of β-catenin mutations was significantly reduced 
by 7ND treatment (Supplemental Table 2). Collectively, these observations would indicate 
that CCL2-CCR2 interactions were also crucially involved in the tumor progression phase 




CCL2 was originally identified as a chemokine, which is chemotactic for monocytes 
and macrophages (14). Although most chemokines can bind several distinct receptors with 
similar affinities, CCL2 utilizes CCR2 as its single specific receptor (19). Subsequent studies 
have unraveled the crucial roles of the CCL2-CCR2 interactions in various chronic 
inflammatory conditions characterized by a macrophage infiltration, such as crescentic 
glomerulonephritis (20), pulmonary hypertension (21), pulmonary fibrosis (22), 
atherosclerosis (23), multiple sclerosis (24), and rheumatoid arthritis (25). Moreover, CCL2 
mRNA and protein expression was augmented in the mucosa of patients with IBD (11-13). In 
a recent study, administration of the antioxidant N-acetyl-L-cysteine (NAC) to UC patients 
had beneficial effects together with down-regulation of CCL2 expression levels (26). We 
consistently observed that CCL2 protein was detected in mononuclear cells infiltrating the 
lamina propria and submucosal areas and produced by endothelial cells at early time points. 
Moreover, genetic deletion of CCR2 protected mice from DSS-induced acute inflammatory 
changes as previously reported (27). Thus, CCL2-CCR2 interactions can initiate colon 
carcinogenesis by inducing inflammation in the colon. 
In addition to hematopoietic cells such as macrophages, CCR2 is expressed also by 
non-hematopoietic cells such as endothelial cells (28), fibroblasts (29), and mesenchymal 
stem cells (30). In line with the previous observation that CCR2 is expressed by prostate 
cancer cells (31), we detected CCR2 expression on some cancer cells as well as by infiltrating 
mononuclear cells in this model. However, the analysis of bone marrow chimeric mice 
revealed that bone marrow-derived CCR2-expressing but not non-bone marrow-derived cells, 
are indispensable for this colon carcinogenesis, although contribution of bone 
marrow-derived endothelial progenitor cells (32) and/or fibrocytes (33), cannot be completely 
excluded. 
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Andreas and colleagues claimed that upon DSS treatment, CCR2- or CCR5-deficient 
mice exhibited reduced acute colitis, but with similar level of macrophage infiltration as WT 
mice (27). On the contrary, combined blockade of CCR2, CCR5, and CXCR3 protected mice 
from DSS-induced colitis along with a reduction in intracolonic infiltration of 
CD11b-positive macrophages (34). We also observed that macrophage infiltration was 
markedly reduced in CCR2-deficient mice after DSS treatment, compared with WT mice. 
Moreover, intracolonic macrophage infiltration was also reduced by two distinct CCL2 
antagonists, 7ND-expressing vector and propagermanium. Thus, CCL2-CCR2 interactions 
regulate intracolonic infiltration of macrophages under our present conditions. 
Solid tumors including colon cancers are infiltrated with leukocytes, which 
sometimes account for up to 50% of tumor mass, the most represented populations being 
lymphocytes and macrophages (35). The presence of lymphocytes is considered as evidence 
of an immunological anti-tumor response, whereas the presence of tumor-associated 
macrophages (TAM) represents a hallmark of cancer-associated inflammation (35). TAM 
originate from circulating monocytes which are attracted by chemotactic factors produced 
locally by tumor cells and resident cells. TAM produce IL-10 and TGF-β to dampen immune 
response to tumor cells and concomitantly promote tumor growth by producing angiogenic 
and growth factors. CCL2 was originally identified as a tumor-derived chemotactic factor for 
macrophages (36). Accumulating evidence indicates that the levels of tumor-derived CCL2 
significantly correlate with TAM density and the depth of invasion in cancers of various 
organs (35). Moreover, experimental studies using xenotransplanted or isotransplanted 
tumors revealed the involvement of the CCL2-CCR2 axis in cancer invasion and metastasis 
(37, 16). 
In order to clarify the roles of the CCL2-CCR2 in the progression phase of this colon 
carcinogenesis model, we utilized two different measures to block CCL2 activity; 
intramuscular injection of 7ND expression vector and administration of propagermanium. 
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The biological activity of CCL2 depends on the integrity of its N-terminus and 7ND, a 
mutant protein lacking N-terminal amino acids 2-8, that can form a heterodimer with 
wild-type CCL2 protein (15), to suppress CCL2 activity (38). Intramuscular transduction of 
7ND-expressing vector can result in continuous intramuscular 7ND protein expression and its 
subsequent secretion into the circulation (39), thereby preventing CCL2-mediated tissue 
injuries such as vascular remodeling (39), atherosclerosis (39), and renal fibrosis after 
reperfusion injury (40). Another CCR2 inhibitor, propagermanium, targets 
glycosylphosphatidylinositol-anchored proteins associated closely with CCR2, and 
selectively inhibits MCP-1/CCR2 signaling (41). Both measures attenuated intracolonic 
macrophage infiltration and neovascularization, and eventually reduced the numbers and 
sizes of colon carcinomas. Thus, it is reasonable to speculate that the CCL2 axis is crucially 
involved in the progression phase of colon carcinogenesis by regulating macrophage 
infiltration. 
TAM can produce various factors to promote tumor growth and angiogenesis. 
Among them, prostaglandin E2 (PGE2) is presumed to be crucially involved in colon 
carcinogenesis because it can induce neovascularization (42) and activate a pathway crucial 
for colon carcinogenesis, the Wnt/β-catenin pathway, through activation of phosphoinositide 
3-kinase/Akt-G protein αs-axin signaling axis (43) and inhibition of glycogen synthase 
kinase-3 (44). COX-2 is an important enzyme in PGE2 generating pathway and its expression 
is highly inducible in various types of cells including macrophages (45). COX-2 protein was 
detected in infiltrating F4/80-positive cells (10) and CCR2-expressing cells. Moreover, CCL2 
can induce COX-2 expression in human monocytes (46). Thus, CCL2 blocking may reduce 
the infiltration of COX-2-expressing F4/80-positive cells and depress COX-2 expression by 
infiltrating macrophages, and eventually inhibit the Wnt signaling pathway and 
neovascularization, resulting in retardation of cancer progression. 
Based on our previous observation that blocking TNF-α reversed colon carcinoma 
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progression even after colon carcinoma was established, we proposed that drugs targeting 
TNF-α may be useful for the treatment of colon cancers, particularly those arising from 
chronic inflammation (10). Blocking CCL2 retarded colon cancer progression in this model 
with similar efficacy as TNF-α blockade, when given after multiple colon tumors were 
developed. Thus, drugs targeting CCL2 may be effective for the treatment of chronic 
inflammation-associated colon cancer, similarly to those targeting TNF-α. Because TNF-α 
has a wide variety of biological functions (9), TNF-α blocking agents can have serious 
adverse effects including the induction of bacterial, tuberculosis, and opportunistic infection 
(47). CCL2 has a limited biological function and therefore, drugs targeting CCL2 might have 
less severe adverse effects than those targeting TNF-α. 
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Figure 1. Tumor formation in WT and CCR2-deficient (CCR2KO) mice after AOM and DSS 
treatment. (A) Tumor numbers. Colons were removed at day 56 to determine the numbers of 
macroscopic tumors. Results are presented as mean±SD (n=10 animals).  **, p<0.01 versus 
WT mice. (B) CCL2 gene expression in the colons of WT mice. The levels of CCL2 mRNA 
were quantified by real-time RT-PCR as described in Materials and Methods, and normalized 
to the level of GAPDH mRNA. *, p<0.05, **, p<0.01 versus untreated (control) mice. (C, D) 
Immunohistochemical detection of CCL2-positive (C) and CCR2-positive cells (D) in the 
colons. Colons were obtained from WT mice at the indicated time points. 
Immunohistochemical analysis was conducted as described in Materials and Methods. 
Representative results from 5 independent animals are shown here. Scale bars, 50 μm. 
 
Figure 2.  Microscopical analysis of colon tissues.  
(A) Colons were removed at the indicated time intervals, fixed and stained with hematoxylin 
and eosin. Representative results from 5 mice are shown here. (B) Immunohistochemical 
staining for β-catenin. Colons were removed at the indicated time intervals from WT and 
CCR2-deficient mice and immunostained with anti-β-catenin antibody as described in 
Materials and Methods. Representative results from 5 mice are shown here. (C) The numbers 
of F4/80-positive cells were counted as described in Materials and Methods and are shown 
here. All values represent the mean + SD (n=10 animals), *, p<0.05, **, p<0.01 vs. untreated 
(control) mice. Scale bars, 50 μm (A), 20 μm (B). 
 
Figure 3. Colon tumor formation in bone marrow chimeric mice. 
Bone marrow chimeric mice were generated and subjected to AOM and DSS treatment as 
described in Materials and Methods. Colons were removed at day 56 and the tumor numbers 
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were determined macroscopically. The bars represent the mean of each group; each symbol 
represents the tumor numbers of each animal (n = 4 to 5), *, p<0.05, **, p<0.01; NS, not 
significant. 
 
Figure 4. COX-2 expression in the colons. 
(A) Quantitative RT-PCR was performed on total RNAs extracted from the colons at the 
indicated time points as described in Materials and Methods. The levels of COX-2 mRNA 
were normalized to the levels of GAPDH mRNA. *, p<0.05, **, p<0.01, vs. untreated mice. 
(B, C) Immunohistochemical detection of COX-2 expressing cells. Colons were obtained 
from WT mice at the indicated time points and immunostained with anti-COX-2 antibody as 
described in Materials and Methods. Representative results from 6 independent animals are 
shown in B. The numbers of COX-2 expressing cells were determined. Mean±SD were 
calculated and are shown in C. *, p<0.05, **, p<0.01, vs. untreated mice. (D) A double-color 
immunofluorescence analysis on COX-2 expression by CCR2-expressing cells. Colons were 
obtained from WT mice and immunolabeled with anti-CCR2 (left panel) and anti-COX-2 
antibodies (middle panel). Fluorescence was digitally merged in the right panel. 
Representative results from 6 independent experiments are shown here. Scale bars, 20 μm (B, 
D). 
 
Figure 5. The effects of 7ND-expressing vector injection on colon carcinogenesis. (A) 
Macroscopic evaluation of the tumors. Colons were removed on day 67 from WT mice, 
injected with 7ND-expressing or with pcDNA3 vector. Representative results from 7 to 8 
independent animals are shown here. (B) The tumor numbers and sizes were determined 
macroscopically. The bars represent the mean of each group. Each symbol represents the 
tumor numbers of each animal or the average size of the tumors of each animal. **, p<0.01 vs. 
WT mice injected with pcDNA3 vector. (C) Colons were processed to hematoxylin and eosin 
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staining and representative results from 6 independent animals are shown here. Scale bar, 50 
μm. (D) F4/80-positive macrophages were enumerated as described in Materials and 
Methods. All values represent the mean + SD (n=5 animals). *, p<0.05, **, p<0.01, vs. WT 
mice injected with pcDNA3 vector. 
 
Figure 6.  The effect of 7ND-expressing vector injection on colon carcinoma progression. 
(A) COX-2 expression after 7ND-expressing vector injection. Quantitative RT-PCR analysis 
for COX-2 mRNA (left panel) and immunohistochemical analysis with anti-COX-2 antibody 
(right panel) were at the indicated time points as described in Materials and Methods. The 
levels of COX-2 mRNA were normalized to the levels of GAPDH mRNA (left panel), while 
the numbers of COX-2-expressing cells were determined on 5 independent animals as 
described in Materials and Methods (right panel). The mean + SD were calculated on all 
values and are shown here. *, p<0.05 vs. WT mice injected with pcDNA3 vector; **, p<0.01, 
vs. WT mice injected with pcDNA3 vector. (B) The vascular areas were determined as 
described in Materials and Methods and are shown in here. *, p<0.05 vs. WT mice injected 
with pcDNA3 vector. (C) The β-catenin nuclear localization ratio was determined as the ratio 
of the numbers of tumor nuclei with β-catenin localization to the total number of tumor 
nuclei per field. At least 5 randomly chosen fields at x 400 magnification were examined. All 
values represent the mean + SD, *, p<0.05, vs. WT mice injected with pcDNA3 vector. (D) 
The numbers of cytokeratin 20-positive cells were determined on 5 randomly chosen visual 
fields at x 400 magnification. All values represent the mean + SD, **, p<0.01, vs. WT mice 
injected with pcDNA3 vector.  
 






